SR-144,528

SR-144,528
Clinical data

ATC code	none
Identifiers
IUPAC name 5-(4-Chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-1H-pyrazole-3-carboxamide
CAS Number	192703-06-3^Y
PubChem (CID)	3081355
IUPHAR/BPS	751
ChemSpider	2338975^N
ChEMBL	CHEMBL381791^N
Chemical and physical data
Formula	C₂₉H₃₄ClN₃O
Molar mass	476.053 g/mol
3D model (Jmol)	Interactive image
SMILES CC1=CC=C(C=C1)CN2C(=CC(=N2)C(=O)N[C@H]3[C@]4(CC[C@H](C4)C3(C)C)C)C5=CC(=C(C=C5)Cl)C
InChI InChI=1S/C29H34ClN3O/c1-18-6-8-20(9-7-18)17-33-25(21-10-11-23(30)19(2)14-21)15-24(32-33)26(34)31-27-28(3,4)22-12-13-29(27,5)16-22/h6-11,14-15,22,27H,12-13,16-17H2,1-5H3,(H,31,34)/t22-,27-,29+/m1/s1^N Key:SUGVYNSRNKFXQM-XRHWURSXSA-N^N
^NY (what is this?) (verify)

SR144528 is a drug that acts as a potent and highly selective CB₂ receptor inverse agonist, with a K_i of 0.6nM at CB₂ and 400nM at the related CB₁ receptor.^[1]^[2] It is used in scientific research for investigating the function of the CB₂ receptor,^[3]^[4]^[5] as well as for studying the effects of CB₁ receptors in isolation, as few CB₁ agonists that do not also show significant activity as CB₂ agonists are available.^[6]^[7]^[8] It has also been found to be an inhibitor of sterol O-acyltransferase, an effect that appears to be independent from its action on CB₂ receptors.^[9]

References

↑ Rinaldi-Carmona, Murielle; Barth, Francis; Millan, José; Derocq, Jean-Marie; Casellas, Pierre; Congy, Christian; Oustric, Didier; Sarran, Martine; Bouaboula, Monsif; Calandra, Bernard; Portier, Marielle; Shire, David; Brelière, Jean-Claude; Fur, Gérard Le (1 February 1998). "SR 144528, the First Potent and Selective Antagonist of the CB₂ Cannabinoid Receptor". Journal of Pharmacology and Experimental Therapeutics. 284 (2): 644–650. ISSN 1521-0103. PMID 9454810.
↑ Portier, Marielle; Rinaldi-Carmona, Murielle; Pecceu, Florence; Combes, Thérèse; Poinot-Chazel, Caroline; Calandra, Bernard; Barth, Francis; Fur, Gérard Le; Casellas, Pierre (1 February 1999). "SR 144528, an Antagonist for the Peripheral Cannabinoid Receptor that Behaves as an Inverse Agonist". Journal of Pharmacology and Experimental Therapeutics. 288 (2): 582–589. ISSN 1521-0103. PMID 9918562.
↑ Gouldson, Paul; Calandra, Bernard; Legoux, Pascale; Kernéis, Aimée; Rinaldi-Carmona, Murielle; Barth, Francis; Le Fur, Gérard; Ferrara, Pascual; Shire, David (28 July 2000). "Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB₂ receptor". European Journal of Pharmacology. 401 (1): 17–25. doi:10.1016/S0014-2999(00)00439-8. PMID 10915832.
↑ Nackley, A. G; Makriyannis, A; Hohmann, A. G (4 July 2003). "Selective activation of cannabinoid CB2 receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation". Neuroscience. 119 (3): 747–757. doi:10.1016/S0306-4522(03)00126-X. PMID 12809695.
↑ Páldy, Eszter; Bereczki, Erika; Sántha, Miklós; Wenger, Tibor; Borsodi, Anna; Zimmer, Andreas; Benyhe, Sándor (1 December 2008). "CB₂ cannabinoid receptor antagonist SR144528 decreases μ-opioid receptor expression and activation in mouse brainstem: Role of CB₂ receptor in pain". Neurochemistry International. 53 (6–8): 309–316. doi:10.1016/j.neuint.2008.08.005. PMID 18804501.
↑ Lay, Lucy; Angus, James A; Wright, Christine E (10 March 2000). "Pharmacological characterisation of cannabinoid CB₁ receptors in the rat and mouse". European Journal of Pharmacology. 391 (1–2): 151–161. doi:10.1016/S0014-2999(00)00062-5. PMID 10720647.
↑ Germanò, Maria Paola; D'Angelo, Valeria; Mondello, Maria Rita; Pergolizzi, Simona; Capasso, Francesco; Capasso, Raffaele; Izzo, Angelo A.; Mascolo, Nicola; Pasquale, Rita De (1 February 2001). "Cannabinoid CB₁-mediated inhibition of stress-induced gastric ulcers in rats". Naunyn-Schmiedeberg's Archives of Pharmacology. 363 (2): 241–244. doi:10.1007/s002100000360. ISSN 1432-1912. PMID 11218077.
↑ Abalo, R.; Cabezos, P. A.; Vera, G.; Fernández-pujol, R.; Martín, M. I. (1 June 2010). "The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212-2 on gastrointestinal motility in the rat". Neurogastroenterology & Motility. 22 (6): 694–e206. doi:10.1111/j.1365-2982.2009.01466.x. ISSN 1365-2982. PMID 20132133.
↑ Thewke, Douglas; Freeman-Anderson, Natalie; Pickle, Theresa; Netherland, Courtney; Chilton, Courtney (3 April 2009). "AM-251 and SR144528 are acyl CoA:cholesterol acyltransferase inhibitors". Biochemical and Biophysical Research Communications. 381 (2): 181–186. doi:10.1016/j.bbrc.2009.02.020. PMC 2665256. PMID 19338772.

Cannabinoids

Phytocannabinoids

Active metabolites: 8,11-DiOH-THC
11-COOH-THC
11-OH-THC

Endocannabinoids

Synthetic
cannabinoids

Classical cannabinoids (dibenzopyrans)	A-40174 A-41988 A-42574 Ajulemic acid AM-087 AM-411 AM-855 AM-905 AM-906 AM-919 AM-926 AM-938 AM-2389 AM-4030 AMG-1 AMG-3 AMG-36 AMG-41 Dexanabinol (HU-211) DMHP Dronabinol HHC HU-210 HU-243 JWH-051 JWH-133 JWH-139 JWH-161 JWH-229 JWH-359 KM-233 L-759,633 L-759,656 Levonantradol (CP 50,5561) Menabitan Nabazenil Nabidrox (Canbisol) Nabilone Nabitan Naboctate O-224 O-581 O-774 O-806 O-823 O-1057 O-1125 O-1191 O-1238 O-2048 O-2113 O-2365 O-2372 O-2373 O-2383 O-2426 O-2484 O-2545 O-2694 O-2715 O-2716 O-3223 O-3226 Parahexyl Pirnabine THC-O-acetate THC-O-phosphate

Non-classical cannabinoids	Cannabicyclohexanol CP 47,497 (C6)-CP 47,497 (C9)-CP 47,497 CP 55,244 CP 55,940 HU-308 HU-320 HU-331 HU-336 HU-345 HU-446 HU-465 HU-910 HUF-101 HUF-102 HUF-103 Nonabine O-1376 O-1422 O-1601 O-1656 O-1657 O-1660 O-1663 O-1871 SPA-229 Tinabinol 2-Isopropyl-5-methyl-1- (2,6-dihydroxy-4-nonylphenyl)cyclohex-1-ene

Benzoylindoles	1-Butyl-3-(2-methoxybenzoyl)indole 1-Butyl-3-(4-methoxybenzoyl)indole 1-Pentyl-3-(2-methoxybenzoyl)indole AM-630 AM-679 AM-694 AM-1241 AM-2233 GW-405,833 (L-768,242) Pravadoline RCS-4 WIN 54,461

Naphthoylindoles	AM-1220 AM-1221 AM-1235 AM-2201 AM-2232 CHM-081 EAM-2201 FUB-JWH-018 JWH-007 JWH-015 JWH-018 JWH-019 JWH-073 JWH-081 JWH-098 JWH-116 JWH-122 JWH-149 JWH-164 JWH-182 JWH-193 JWH-198 JWH-200 JWH-210 JWH-398 JWH-424 MAM-1220 MAM-2201 NE-CHMIMO

Naphthoylindazoles	THJ-018 THJ-2201

Pyrrolobenzoxazines	WIN 55,212-2

Naphthylmethylindoles	JWH-175 JWH-176 JWH-184 JWH-185 JWH-192 JWH-194 JWH-195 JWH-196 JWH-197 JWH-199

Phenylacetylindoles	Cannabipiperidiethanone JWH-167 JWH-203 JWH-249 JWH-250 JWH-251 JWH-302 RCS-8

Indole-3-carboxamides	5F-ADBICA 5F-NNE1 5F-PCN 5F-SDB-006 AB-FUBICA AB-PICA ADBICA ADB-FUBICA APICA CUMYL-BICA CUMYL-PICA CUMYL-5F-PICA FDU-NNE1 MDMB-CHMICA MMB-2201 MN-25 (UR-12) NNE1 PX-1 Org 28312 Org 28611 SDB-006 STS-135

Indole-3-carboxylates	5F-PB-22 FDU-PB-22 FUB-PB-22 QUCHIC (BB-22) QUPIC (PB-22) NM-2201

Tetramethylcyclo- propanoylindoles	5Br-UR-144 5Cl-UR-144 A-796,260 A-834,735 FUB-144 UR-144 XLR-11 XLR-12

Indazole-3- carboxamides	5Cl-APINACA 5F-ADB 5F-ADB-PINACA 5F-AMB 5F-APINACA 5F-CUMYL-PINACA 5F-EMB-PINACA AB-CHMINACA AB-FUBINACA AB-FUBINACA 2-fluorobenzyl isomer AB-PINACA ADB-CHMINACA ADB-FUBINACA ADB-PINACA ADAMANTYL-THPINACA ADSB-FUB-187 AMB-CHMINACA AMB-FUBINACA APINACA (AKB48) APP-FUBINACA CUMYL-PINACA CUMYL-THPINACA EMB-FUBINACA FUB-APINACA MDMB-FUBINACA MDMB-CHMINACA MN-18 PX-2 PX-3

Tetramethylcyclo- propanoylindazoles	FAB-144

Naphthoylpyrroles	JWH-030 JWH-147 JWH-307 JWH-369 JWH-370

Eicosanoids	AM-883 AM-1346 ACEA ACPA Methanandamide (AM-356) O-585 O-689 O-1812 O-1860 O-1861

Pyrazolecarboxamides	5F-AB-FUPPYCA AB-CHFUPYCA AB-CHMFUPPYCA

Others	4-HTMPIPO 5F-PY-PICA 5F-PY-PINACA 5F-3-pyridinoylindole A-836,339 A-955,840 Abnormal cannabidiol AB-001 BzODZ-EPyr AM-1248 AM-1714 AZ-11713908 BAY 38-7271 BAY 59-3074 BIM-018 CB-13 CB-86 CBS-0550 FUBIMINA GSK-554,418A GW-842,166X JTE 7-31 LASSBio-881 LBP-1 Leelamine MDA-7 MDA-19 MEPIRAPIM NESS-040C5 NMP-7 O-889 O-1269 O-1270 O-1399 O-1602 O-2220 PF-03550096 PSB-SB-1202 PTI-1 PTI-2 QMPSB S-444,823 SER-601 Tedalinab URB-447 VSN-16 WIN 56,098

Allosteric CBR ligands

Org 27569
Org 27759
Org 29647
RTI-371
Pregnenolone

Endocannabinoid
enhancers
(inactivation inhibitors)

Anticannabinoids
(antagonists/inverse
agonists/antibodies)

AM-251
AM-281
AM-630
AM-1387
AM-4113
AM-6527
AM-6545
BML-190
Brizantin (Бризантин)
CAY-10508
CB-25
CB-52
CB-86
Dietressa (Диетресса)
Drinabant (AVE1625)
Hemopressin
Ibipinabant (SLV319)
JTE-907
LH-21
LY-320,135
MDA-77
MJ-15
MK-9470
NESS-0327
NIDA-41020
O-606
O-1184
O-1248
O-1918
O-2050
O-2654
Otenabant (CP-945,598)
PF-514273
PipISB
PSB-SB-487
Rimonabant (SR141716)
Rosonabant (E-6776)
SR-144,528
Surinabant (SR147778)
Taranabant (MK-0364)
TM-38837
VCHSR

See also: Cannabinoidergics (cannabinoids by pharmacology)
List of: AM cannabinoids
JWH cannabinoids
Designer drugs § Synthetic cannabimimetics

Cannabinoidergics

Receptor
(ligands)

CB₁	Agonists (abridged; see here for more): 2-AG 2-AGE (noladin ether) 11-Hydroxy-THC α-Amyrin β-Amyrin AB-CHMINACA AM-1172 AM-1220 AM-1221 AM-1235 AM-2201 AM-2232 Anandamide Arvanil AZ-11713908 Cannabinol CB-13 CP 47,497 CP 55,940 Dimethylheptylpyran DEA ECG EGCG Epicatechin Gallocatechol (gallocatechin) Honokiol HU-210 JWH-007 JWH-015 JWH-018 JWH-073 Kavain L-759,633 Levonantradol Menabitan Nabilone Nabitan NADA O-1812 Oleamide Pravadoline Serinolamide A THC (dronabinol) UR-144 WIN 55,212-2 Yangonin Antagonists: AM-251 AM-6545 Cannabidiol Cannabigerol Drinabant Falcarinol (carotatoxin) Hemopressin Ibipinabant LY-320,135 MK-9470 NESS-0327 O-2050 Otenabant PF-514273 PipISB Rimonabant Rosonabant Surinabant Taranabant THCV TM-38837 VCHSR Virodhamine Antibodies: Brizantin (Бризантин) Dietressa (Диетресса) Unknown/unsorted: MAFP

CB₂	Agonists: 2-AG 2-AGE (noladin ether) 3,3'-Diindolylmethane 4-O-Methylhonokiol α-Amyrin β-Amyrin A-796,260 A-834,735 A-836,339 AM-1172 AM-1221 AM-1235 AM-1241 AM-2232 Anandamide AZ-11713908 Cannabinol Caryophyllene CB-13 CBS-0550 CP-55,940 GW-405,833 (L-768,242) GW-842,166X HU-308 JTE 7-31 JWH-007 JWH-015 JWH-018 JWH-73 JWH-133 L-759,633 L-759,656 Magnolol MDA-19 Nabitan NADA PF-03550096 S-444,823 SER-601 Serinolamide A UR-144 Tedalinab THC (dronabinol) THCV Tetrahydromagnolol Virodhamine Antagonists: 4-O-Methylhonokiol AM-630 BML-190 Cannabidiol Honokiol JTE-907 SR-144,528 WIN 54,461 WIN 56,098

GPR18	Agonists: Abnormal cannabidiol ACPA AM251 Anandamide Cannabidiol NADGly THC (dronabinol) O-1602 Antagonists: CID-85469571 O-1918

GPR55	Agonists: 2-AGE (noladin ether) 2-ALPI Abnormal cannabidiol AM-251 CID1011163 CID1252842 CID1792579 CP 55,940 GSK-494581A Lysophosphatidylinositol ML-184 ML-185 ML-186 O-1602 Oleoylethanolamide Palmitoylethanolamide THC (dronabinol) Antagonists: Cannabidiol CID-16020046 ML-191 ML-192 ML-193 O-1918 PSB-SB-487 PSB-SB-1202 PSB-SB-1203 Tetrahydromagnolol

GPR119	Agonists: 2-Oleoylglycerol Anandamide APD668 AR-231,453 AS-1269574 MBX-2982 N-Oleoyldopamine Oleoylethanolamide Olvanil PSN-375,963 PSN-632,408

Transporter
(modulators)

eCBTs	Inhibitors: 5'-DMH-CBD AM-404 AM-1172 Arachidonoyl serotonin Arvanil Cannabidiol Guineensine LY-2183240 O-2093 OMDM-2 Paracetamol (acetaminophen) SB-FI-26 UCM-707 URB-597 VDM-11 WOBE490 WOBE491 WOBE492

Enzyme
(modulators)

FAAH	Inhibitors: 4-Nonylphenylboronic acid AACOCF₃ AM-404 Arachidonoyl serotonin BIA 10-2474 Biochanin A Genistein IDFP JNJ-1661010 JNJ-42165279 JZL-195 Kaempferol LY-2183240 MAFP Palmitoylisopropylamide Paracetamol (acetaminophen) PF-3845 PF-04457845 PF-750 SA-47 SA-57 TAK 21d TC-F 2 UCM710 URB-597 Activators: PDP-EA

MAGL	Inhibitors: ABX-1431 IDFP JJKK 048 JW 642 JZL-184 JZL-195 JZP-361 KML 29 MAFP MJN110 NAM Pristimerin URB-602

ABHD6	Inhibitors: JZP-169 JZP-430 KT182 KT185 KT195 KT203 LEI-106 ML294 ML295 ML296 UCM710 WWL-70

ABHD12	Inhibitors: Betulinic acid Maslinic acid MAFP Oleanolic acid Orlistat (tetrahydrolipstatin) Ursolic acid

Others

Precursors: Phosphatidylethanolamine
NAPE
Diacylglycerol

Others: 2-PG (directly potentiates activity of 2-AG at CB₁ receptor)
ARN-272 (FAAH-like anandamide transporter inhibitor)

See also: Cannabinoids (cannabinoids by structure)

This article is issued from Wikipedia - version of the 8/30/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.

SR-144,528

See also

References